De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sight Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Sight Sciences' is Paul Badawi, benoemd in Jan2011, heeft een ambtstermijn van 13.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.90M, bestaande uit 15.6% salaris en 84.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.41% van de aandelen van het bedrijf, ter waarde $ 36.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 4.6 jaar.

Belangrijke informatie

Paul Badawi

Algemeen directeur

US$3.9m

Totale compensatie

Percentage CEO-salaris	15.6%
Dienstverband CEO	13.8yrs
Eigendom CEO	11.4%
Management gemiddelde ambtstermijn	4.5yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Aug 15

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 19

Analysts Have Been Trimming Their Sight Sciences, Inc. (NASDAQ:SGHT) Price Target After Its Latest Report

Mar 26

Analyse CEO-vergoeding

Hoe is Paul Badawi's beloning veranderd ten opzichte van Sight Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$55m
Dec 31 2023	US$4m	US$610k	-US$56m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$80m
Dec 31 2022	US$6m	US$580k	-US$86m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$80m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$9m	US$424k	-US$63m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$497k	US$360k	-US$35m

Compensatie versus markt: De totale vergoeding ($USD 3.90M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Badawi (49 yo)

13.8yrs

Tenure

US$3,902,022

Compensatie

Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Badawi	Co-Founder	13.8yrs	US$3.90m	11.41% $ 34.8m
David Badawi	Founder	13.8yrs	geen gegevens	3.5% $ 10.7m
Alison Bauerlein	CFO & Treasurer	1.5yrs	US$1.85m	0.059% $ 180.1k
Matthew Link	Chief Commercial Officer	1.1yrs	US$2.36m	geen gegevens
Sam Park	Chief Operating Officer	4.6yrs	US$1.86m	0.14% $ 440.7k
Jeremy Hayden	Chief Legal Officer	4.5yrs	geen gegevens	0.042% $ 128.4k
Steve Tamayo	VP and Chief Ethics & Compliance Officer	1.4yrs	geen gegevens	geen gegevens
Reay Brown	Chief Medical Officer	6yrs	geen gegevens	geen gegevens
Stephen Thau	Secretary	no data	geen gegevens	geen gegevens
Jim Rodberg	VP of Finance & Corporate Controller	no data	geen gegevens	0.0014% $ 4.2k

4.5yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SGHT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Badawi	Co-Founder	13.8yrs	US$3.90m	11.41% $ 34.8m
David Badawi	Founder	13.8yrs	geen gegevens	3.5% $ 10.7m
Erica Rogers	Independent Director	4.9yrs	US$182.30k	0.22% $ 669.7k
Donald Zurbay	Independent Director	4.3yrs	US$187.50k	0.20% $ 606.6k
Brenda Becker	Independent Director	2.6yrs	US$167.33k	0.0073% $ 22.3k
Staffan Encrantz	Independent Chairman	7yrs	US$207.91k	4.37% $ 13.3m
Tamara Fountain	Independent Director	2.3yrs	US$401.06k	0.042% $ 127.8k
Catherine Mazzacco	Independent Director	1.3yrs	US$256.34k	0.036% $ 110.3k

4.6yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SGHT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Sight Sciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Co-Founder recently sold US$81k worth of stock

CFO & Treasurer recently sold US$71k worth of stock

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Co-Founder recently sold US$64k worth of stock

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Recent updates

Price target increased by 14% to US$7.38

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Narrows Earnings Guidance for the Full Year 2024

Sight Sciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Co-Founder recently sold US$81k worth of stock

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma

CFO & Treasurer recently sold US$71k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Sight Sciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study

Co-Founder recently sold US$64k worth of stock

Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024

New minor risk - Insider selling

Sight Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. announced that it expects to receive $65 million in funding

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Sight Sciences, Inc. Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology

Independent Chairman recently bought US$278k worth of stock

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Price target decreased by 49% to US$3.13

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

New minor risk - Market cap size

Sight Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Chief Operating Officer exercised options to buy US$130k worth of stock.

Sight Sciences, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 8.1% to US$10.48

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sight Sciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Sight Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 12% to US$12.80

Sight Sciences Announces Appointment of Catherine Mazzacco as New Director

Sight Sciences Two Year Multicenter Study Results Shows Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with A Procedure Enabled with the Omni Surgical System Technology

Sight Sciences, Inc. Announces 12-Month Results from the First Minimally Invasive Glaucoma Surgery

First quarter 2023 earnings: EPS exceeds analyst expectations

Sight Sciences Reaffirms Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Announces Executive Changes

Price target increased to US$14.60

Sight Sciences, Inc. Reports Improvements in Signs and Symptoms of Dry Eye Disease from A Single Tearcare

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sight Sciences, Inc. Provides Revenue Guidance for Full Year 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients

Sight Sciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sight Sciences, Inc. Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare(R) System Compared to Lipiflow in Patients with Advanced Dry Eye Disease (DED)

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare(R) System vs Restasis

Sight Sciences Introduces the Sion(Tm) Surgical Instrument -- the First Bladeless Device Used in Goniotomy

Sight Sciences Grows Portfolio Amid Reimbursement Pressure

Sight Sciences, Inc. Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI(R) Surgical System in Patients with Open Angle Glaucoma

Sight Sciences, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$14.50